An Antibody Microarray for Histone Modifications

Informacje na temat projektu

HisMoDetect

Identyfikator umowy o grant: 680600

DOI

10.3030/680600

Projekt został zamknięty

Data podpisania przez KE 30 Lipca 2015

Data rozpoczęcia 1 Października 2015

Data zakończenia 31 Marca 2017

Finansowanie w ramach

• EXCELLENT SCIENCE - European Research Council (ERC)

Koszt całkowity

€ 150 000,00

Wkład UE

€ 150 000,00

Koordynowany przez

THE HEBREW UNIVERSITY OF JERUSALEM
Israel

Periodic Reporting for period 1 - HisMoDetect (An Antibody Microarray for Histone Modifications)

Okres sprawozdawczy: 2015-10-01 do 2017-03-31

Podsumowanie kontekstu i ogólnych celów projektu

Histones are the major structural proteins of eukaryotic DNA. Two copies each of the core histones, H2A, H2B, H3 and H4, form the core nucleosome, the basic unit of chromatin. Histone tails protrude from the nucleosome structure and are subject to a variety of post-translational modifications on multiple residues, including methylation, acetylation,phosphorylation, sumoylation, ubiquitination and polyribosylation. These histone modifications dictate local and global structure of chromatin, rendering it active and decondensed (‘euchromatic’) or suppressed and compact (‘heterochromatic’) by the recruitment of chromatin-binding proteins that recognize and associate with specific modifications. Histone modifications are therefore the basic regulatory unit of gene expression, genomic silencing, developmental programs, cell division and essentially all cellular processes. Understanding this so-called ‘epigenetic’ landscape is therefore vital for all biological mechanisms.
Currently a Western blot is required in order to determine the state of each of the dozens of different histone modifications. Because of the growing number of histone modifications, this procedure is time consuming and labour intensive. Here, we developed an antibody microarray to monitor the levels of all histone modifications simultaneously. This method is essentially useful for any tissue or cell type in any biological process, for diagnosis, prognosis and drug screening. In addition to basic research, our platform will enable fast and reliable screening for epigenetic effects of existing and novel drugs.
We are now in a licencing process of this technology, as legal contracts are being reviewed by our legal department for a potential agreement with Diagenode - a leading epigenetic company.